



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 164816

TO: Tamthom Truong
Location: REM-5B19/5C19
Art Unit: 1624
Wednesday, September 07, 2005

Case Serial Number: 10/023099

From: Paul Schulwitz
Location: Biotech-Chem Library
REM-1A65
Phone: 571-272-2527

Paul.schulwitz@uspto.gov

Search Notes

Examiner Truong,

Please review the attached search results.

If you have any questions or if you would like to refine the search query, please feel free to contact me at any time.

Thank you for using STIC search services!

Paul Schulwitz
Technical Information Specialist
REM-1A65
571-272-2527

THIS PAGE BLANK (CSPT0)



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact:*

Mary Hale, Information Branch Supervisor
Remsen Bldg. 01 D86
571-272-2507

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.



THIS PAGE BLANK (USPTO)

THIS PAGE IS INTENTIONALLY LEFT BLANK (USPTO)

=> d his ful

(FILE 'HOME' ENTERED AT 12:51:53 ON 07 SEP 2005)

FILE 'REGISTRY' ENTERED AT 12:52:08 ON 07 SEP 2005

L1 STR
L2 19 SEA SSS SAM L1
L3 238 SEA SSS FUL L1

FILE 'HCAPLUS' ENTERED AT 12:56:19 ON 07 SEP 2005

L4 18 SEA ABB=ON PLU=ON L3

FILE 'BEILSTEIN' ENTERED AT 12:56:38 ON 07 SEP 2005

L5 0 SEA SSS FUL L1

FILE 'HCAPLUS' ENTERED AT 12:57:09 ON 07 SEP 2005

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 SEP 2005 HIGHEST RN 862534-94-9

DICTIONARY FILE UPDATES: 6 SEP 2005 HIGHEST RN 862534-94-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Sep 2005 VOL 143 ISS 11
FILE LAST UPDATED: 6 Sep 2005 (20050906/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BEILSTEIN
FILE RELOADED ON OCTOBER 20, 2002
FILE LAST UPDATED ON JUNE 29, 2005

FILE COVERS 1771 TO 2005.
FILE CONTAINS 9,271,550 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *





NEW

* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.
* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

=> d stat que l4
L1 STR

N@20
C~N
@21 22

CH2Cy
@25 26



VAR G1=46/47/39

VAR G2=CY/25

VAR G3=20/21

NODE ATTRIBUTES:

NSPEC IS RC AT 20

NSPEC IS RC AT 22

CONNECT IS E2 RC AT 1

CONNECT IS E2 RC AT 5

CONNECT IS E2 RC AT 11

CONNECT IS E2 RC AT 13

CONNECT IS E1 RC AT 19

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 49

STEREO ATTRIBUTES: NONE

L3 238 SEA FILE=REGISTRY SSS FUL L1

L4 18 SEA FILE=HCAPLUS ABB=ON PLU=ON L3

=> d l4 ibib abs hitstr 1-18

L4 ANSWER 1 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:638739 HCAPLUS

DOCUMENT NUMBER: 143:159556

TITLE: Novel pharmaceutical combinations containing scopine or tropic acid esters and EGfR-kinase inhibitors

INVENTOR(S): Pieper, Michael P.; Pohl, Gerald; Jung, Birgit; Pairet, Michel

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065687	A1	20050721	WO 2005-EP9	20050104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004001607	A1	20050811	DE 2004-102004001607	20040109
PRIORITY APPLN. INFO.:			DE 2004-102004001607A	20040109

GI




AB The invention relates to novel pharmaceutical compns. based on compds. of general formula (I) wherein X and the groups A, B, R, R1, R2, R3, R3', R4 and R4' have the designations cited in the claims and in the description, and EGFR-kinase inhibitors. The invention also relates to methods for the production of said compns., and to the use of the same for the treatment of respiratory illnesses. Thus an inhalation powder contained (µg/capsule): scopine or tropic acid ester 60; 4-[(3-Chloro-4-fluorophenyl)amino]-6-[2-((S)-6-methyl-2-oxomorpholine-4-yl)ethoxy]-7-methoxyquinazoline 3500; lactose 3440.

IT 314771-10-3 314771-31-8 402570-00-7
 402855-53-2 402855-58-7 439081-17-1
 439081-18-2 439081-24-0 439081-26-2
 439081-30-8 439081-39-7 439081-40-0
 439081-48-8 573649-57-7 858865-12-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical combinations containing scopine or tropic acid esters and EGFR-kinase inhibitors)


RN 314771-10-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(dimethylamino)-(9CI) (CA INDEX NAME)



RN 314771-31-8 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 402570-00-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2S)-2-(methoxymethyl)-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-53-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-58-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3S]-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 439081-17-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3R]-tetrahydro-3-furanyloxy]-6-quinazoliny]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439081-18-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3S]-tetrahydro-3-furanyloxy]-6-quinazoliny]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 439081-24-0 HCAPLUS


CN 2-Butenamide, 4-[bis(2-methoxyethyl)amino]-N-[4-[(3-chloro-4-

fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]-
(9CI) (CA INDEX NAME)




RN 439081-26-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-[(2-methoxyethyl)methylamino]- (9CI) (CA INDEX NAME)



RN 439081-30-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(cyclopropylmethylamino)- (9CI) (CA INDEX NAME)




RN 439081-39-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2R)-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439081-40-0 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2S)-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 439081-48-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2-methoxyethyl)methylamino]- (9CI) (CA INDEX NAME)




RN 573649-57-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)



RN 858865-12-0 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]-4-(2-methyl-6-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:586215 HCAPLUS

DOCUMENT NUMBER: 143:120526

TITLE: Pharmaceutical compositions based on anticholinergics and additional active ingredients

INVENTOR(S): Pairet, Michel; Pieper, Michael P.; Meade, Christopher
John Montague; Reichl, Richard; Schmelzer, Christel;
Jung, Birgit

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany
SOURCE: U.S. Pat. Appl. Publ., 50 pp., Cont.-in-part of U.S.
Ser. No. 824,391.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 14

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005148562	A1	20050707	US 2004-6940	20041208
DE 10062712	A1	20020620	DE 2000-10062712	20001215
DE 10063957	A1	20020627	DE 2000-10063957	20001220
DE 10110772	A1	20020912	DE 2001-10110772	20010307
DE 10111058	A1	20020912	DE 2001-10111058	20010308
DE 10113366	A1	20020926	DE 2001-10113366	20010320
DE 10138272	A1	20030227	DE 2001-10138272	20010810
US 2002151541	A1	20021017	US 2001-7182	20011019
US 2002183292	A1	20021205	US 2001-86145	20011019
US 2002137764	A1	20020926	US 2001-40196	20011025
US 2002122773	A1	20020905	US 2001-27662	20011220
DE 10206505	A1	20030828	DE 2002-10206505	20020216
US 2002169181	A1	20021114	US 2002-92116	20020306
US 6620438	B2	20030916		
US 2002193393	A1	20021219	US 2002-93240	20020307
US 2002183347	A1	20021205	US 2002-100659	20020318
US 6608054	B2	20030819		
US 2003158196	A1	20030821	US 2003-360064	20030207
US 2003181478	A1	20030925	US 2003-395777	20030324
US 6890517	B2	20050510		
US 2003203925	A1	20031030	US 2003-413065	20030414
US 2003212075	A1	20031113	US 2003-419358	20030421
US 6696042	B2	20040224		
US 2004024007	A1	20040205	US 2003-613783	20030703
US 2004151770	A1	20040805	US 2004-763894	20040123
US 2004161386	A1	20040819	US 2004-775901	20040210
US 2004176338	A1	20040909	US 2004-776757	20040211
US 2004192675	A1	20040930	US 2004-824391	20040414
US 2005147564	A1	20050707	US 2005-68134	20050228
PRIORITY APPLN. INFO.:			DE 2000-10054042	A 20001031
			US 2000-253613P	P 20001128
			DE 2000-10062712	A 20001215
			DE 2000-10063957	A 20001220
			US 2000-257220P	P 20001221
			US 2000-257221P	P 20001221
			DE 2001-10110772	A 20010307
			DE 2001-10111058	A 20010308

same assignee

DE 2001-10113366	A	20010320
US 2001-281653P	P	20010405
US 2001-281857P	P	20010405
US 2001-281874P	P	20010405
DE 2001-10138272	A	20010810
US 2001-314599P	P	20010824
US 2001-7182	B1	20011019
US 2001-86145	B1	20011019
US 2001-27662	B1	20011220
DE 2002-10206505	A	20020216
US 2002-92116	A1	20020306
US 2002-93240	B1	20020307
US 2002-100659	A1	20020318
US 2002-369213P	P	20020401
US 2003-360064	A2	20030207
US 2003-413065	B2	20030414
US 2003-419358	A1	20030421
US 2003-613783	A2	20030703
US 2004-763894	A2	20040123
US 2004-775901	A2	20040210
US 2004-776757	A2	20040211
US 2004-824391	A2	20040414
US 2001-40196	B1	20011025
US 2003-395777	A1	20030324

AB A pharmaceutical composition comprising an anticholinergic and at least one addnl. active ingredient selected from among corticosteroids, dopamine agonists, PDE-IV inhibitors, NK1-antagonists, endothelin antagonists, antihistamines, and EGFR-kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases. Among a number of compds. prepared was N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-[4-[(3-hydroxypropyl)methylamino]piperidin-1-yl]-N-methyl-2-phenylacetamide. Inhalable powders include a formulation containing tiotropium bromide, budesonide, and lactose.

IT 573649-61-3


RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. based on anticholinergics and addnl. active ingredients)

RN 573649-61-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3S)-tetrahydro-3-furanyl]methoxy]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




IT 402569-87-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(pharmaceutical compns. based on anticholinergics and addnl. active ingredients)

RN 402569-87-3 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxy-3-methoxypropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 290302-19-1P 314771-10-3P 314771-31-8P

402569-98-6P 402855-52-1P 402855-53-2P

402855-58-7P 439081-17-1P 439081-18-2P

439081-26-2P 439081-30-8P 439081-39-7P


439081-40-0P 439081-48-8P 573649-57-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. based on anticholinergics and addnl. active ingredients)

ingredients)


RN 290302-19-1 HCAPLUS

CN β -Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 314771-10-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 314771-31-8 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 402569-98-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R)-2-(methoxymethyl)-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-52-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2S)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-53-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-58-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3-(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-17-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-18-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-26-2 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-

quinazolinyl]-4-[(2-methoxyethyl)methylamino]- (9CI) (CA INDEX NAME)



RN 439081-30-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(cyclopropylmethylamino)- (9CI) (CA INDEX NAME)




RN 439081-39-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(2R)-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 439081-40-0 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2-(2S)-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 439081-48-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2-methoxyethyl)methylamino]- (9CI) (CA INDEX NAME)



RN 573649-57-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:349007 HCAPLUS

DOCUMENT NUMBER: 142:392435

TITLE: Synthesis of (oxobutenyl)quinazolines and derivatives for treating cancer and other diseases

INVENTOR(S): Soyka, Rainer; Rall, Werner; Schnaubelt, Juergen; Sieger, Peter; Kulinna, Christian

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany

SOURCE: U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005085495	A1	20050421	US 2004-941116	20040915
DE 10349113	A1	20050512	DE 2003-10349113	20031017
WO 2005037824	A2	20050428	WO 2004-EP11378	20041012
WO 2005037824	A3	20050721		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	DE 2003-10349113	A	20031017
	US 2003-517777P	P	20031106

OTHER SOURCE(S): MARPAT 142:392435

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to an improved process for preparing 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(S)-tetrahydrofuran-3-yloxy]quinazoline and related aminocrotonyl compds. I [Ra = CH₂Ph, CH(Ph)Me, 3-Cl-4-FC₆H₃, R₃, R₄ = C₁-C₄-alkyl, X = C, N] and the preparation of a suitable salt of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(S)-tetrahydrofuran-3-yloxy]-quinazoline for use as a pharmaceutically active substance. For example, reacting di-Et phosphonoacetic acid with quinazolinediamine II gave the corresponding phosphonate which was condensed with the aldehyde derived from (dimethylamino)acetaldehyde diethylacetal to give oxobutenyl compound III. Reaction of III with maleic acid gave the maleate salt.

IT 850140-72-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of (oxobutenyl)quinazolines and derivs. for treating cancer and diseases of the respiratory tract, lungs, gastrointestinal tract, bile duct, and gallbladder)

RN 850140-72-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 850140-73-7P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of (oxobutenyl)quinazolines and derivs. for treating cancer and diseases of the respiratory tract, lungs, gastrointestinal tract, bile duct, and gallbladder and crystal structure)


RN 850140-73-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 850140-72-6
CMF C24 H25 Cl F N5 O3


Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:120748 HCAPLUS
DOCUMENT NUMBER: 142:219295
TITLE: Preparation of quinazolines as tyrosine kinase inhibitors for the treatment of inflammatory illnesses
INVENTOR(S): Jung, Birgit; Pueschner, Hubert
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany;
Boehringer Ingelheim Pharma GmbH & Co. KG
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011701	A1	20050210	WO 2004-EP8185	20040722
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

DE 10334226

A1

20050217

DE 2003-10334226

20030728

US 2005059661

A1

20050317

US 2004-899817

20040727

PRIORITY APPLN. INFO.:

DE 2003-10334226

A


20030728

US 2003-495540P

P

20030815

GI



I

AB The title compds. and their pharmaceutically acceptable salts were claimed to be useful for the treatment of inflammatory illnesses. In cigarette smoke induced inflammatory assays, 5-examples of the title compds. exhibited ID50 [mg/kg] values ranging from 0.2-1.1, e.g., the ID50 value of quinazoline I was 0.3.


IT 439081-24-0P 439081-25-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolines as tyrosine kinase inhibitors for the treatment of inflammatory illnesses)


RN 439081-24-0 HCAPLUS

CN 2-Butenamide, 4-[bis(2-methoxyethyl)amino]-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 439081-25-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:965067 HCAPLUS

DOCUMENT NUMBER: 141:406039

TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis

INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin
Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;
Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
WO 2004096224	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

EP 1473043 A1 20041103 EP 2003-9587 20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: EP 2003-9587 A 20030429
EP 2004-508 A 20040113
EP 2004-1171 A 20040121

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amts. of specific active compds. and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compds. and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preps. The pharmaceutical combination can include selected protein tyrosine kinase receptor antagonists and further chemotherapeutic or naturally occurring semisynthetic or synthetic agents.

IT 439081-18-2 790241-29-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(drug combinations for diseases involving cell proliferation and migration or apoptosis or angiogenesis including protein tyrosine kinase receptor antagonists and radiotherapy)

RN 439081-18-2 HCAPLUS

CN 2-Butenamide, N- [4- [(3-chloro-4-fluorophenyl) amino] -7- [[(3S)-tetrahydro-3-furanyl]oxy] -6-quinazolinyl] -4- (dimethylamino) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 790241-29-1 HCAPLUS

CN 2-Butenamide, N- [4- [(3-chloro-4-fluorophenyl) amino] -7- [[(3S)-tetrahydro-3-furanyl]oxy] -6-quinazolinyl] -4- (tetrahydro-1,4-oxazepin-4(5H)-yl) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



L4 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:719893 HCAPLUS

DOCUMENT NUMBER: 141:243560

TITLE: Preparation of 4-anilinoquinazolines as tyrosine kinase inhibitors for the treatment of tumors

INVENTOR(S): Himmelsbach, Frank; Solca, Flavio

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

SOURCE: Ger. Offen., 21 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10307165	A1	20040902	DE 2003-10307165	20030220
US 2005107358	A1	20050519	US 2004-778985	20040213
WO 2004074263	A1	20040902	WO 2004-EP1398	20040214
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI, NI, NO				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: DE 2003-10307165 A 20030220
US 2003-452280P P 20030305

OTHER SOURCE(S): MARPAT 141:243560
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, alkyl; R2 = (un)substituted Ph, benzyl, 1-phenylethyl; R3 = H, halo, OH, etc.; R4, R5 = H, alkyl; X = C(CN), N

with provisos; Z = (un)substituted heterocycle] and their pharmaceutically acceptable salts and formulations were prepared. For example, coupling of 4-[2,2-dimethoxyethyl]homomorpholine and phosphonate II, e.g., prepared from di-Et carboxymethylphosphonate and N4-(3-chloro-4-fluorophenyl)-7-[[[(3S)-tetrahydro-3-furanyl]oxy]-4,6-quinazolinediamine, afforded claimed anilinoquinazoline III in 63% yield. In human epidermal growth factor receptor binding assays, anilinoquinazoline III exhibited an IC₅₀ value of 1.5 nM. Compds. I are claimed useful for the treatment of tumors, i.e., prostate benign hyperplasia.

IT 749879-39-8P 749879-45-6P 749879-46-7P
749879-47-8P 749879-48-9P 749879-49-0P
749879-50-3P 749879-51-4P 749879-52-5P
749879-53-6P 749879-54-7P 749879-55-8P
749879-56-9P 749879-58-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of 4-anilinoquinazolines as tyrosine kinase inhibitors for the treatment of tumors)

RN 749879-39-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-, (2E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 749879-45-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutyloxy)-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-, (2E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 749879-46-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 749879-47-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclohexyloxy)-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 749879-48-9 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 749879-49-0 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentylmethoxy)-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 749879-50-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3-(cyclopentylmethoxy)-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)]-, (2E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 749879-51-4 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-3-yl)oxy]-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-, (2E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 749879-52-5 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)oxy]-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 749879-53-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2R]-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-, (2E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 749879-54-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(2S)-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-, (2E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 749879-55-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-3-furanyl)methoxy]-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-, (2E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 749879-56-9 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 749879-58-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3,4-difluorophenyl)amino]-7-[[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(tetrahydro-1,4-oxazepin-4(5H)-yl)-, (2E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




L4 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:41317 HCAPLUS
 DOCUMENT NUMBER: 140:99649
 TITLE: Pharmaceutical compositions for the treatment of
 respiratory tract diseases comprising novel
 anticholinergic agents and inhibitors of EGFR-kinase
 INVENTOR(S): Pairet, Michel; Meade, Christopher John Montague;
 Pieper, Michael P.
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany
 SOURCE: PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004775	A1	20040115	WO 2003-EP6788	20030626
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10230751	A1	20040122	DE 2002-10230751	20020709
CA 2492037	AA	20040115	CA 2003-2492037	20030626
BR 2003012507	A	20050412	BR 2003-12507	20030626
EP 1521595	A1	20050413	EP 2003-762525	20030626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004048887	A1	20040311	US 2003-614382	20030707
US 2005165013	A1	20050728	US 2005-87153	20050323
PRIORITY APPLN. INFO.:				
			DE 2002-10230751	A 20020709
			US 2002-407746P	P 20020903
			WO 2003-EP6788	W 20030626
			US 2003-614382	A1 20030707


OTHER SOURCE(S): MARPAT 140:99649
 AB The invention relates to novel pharmaceutical compns. comprising novel

anticholinergic agents and EGFR-kinase inhibitors, method for production and use thereof in the treatment of respiratory diseases. The synthesis of several EGFR-kinase inhibitors is given. Thus an inhalation capsule contained (microgram/capsule): 2,2-Diphenylpropionic acid scopine ester methobromide 60; EGFR kinase inhibitor 3500; lactose 3440.


IT 290302-19-1P 314771-10-3P 314771-31-8P
 402569-98-6P 402855-52-1P 402855-53-2P
 402855-58-7P 439081-17-1P 439081-18-2P
 439081-26-2P 439081-30-8P 439081-39-7P
 439081-40-0P 439081-48-8P 573649-57-7P
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (pharmaceutical compns. for treatment of respiratory tract diseases
 comprising anticholinergic agents and inhibitors of EGFR-kinase)
 RN 290302-19-1 HCAPLUS
 CN β -Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 314771-10-3 HCAPLUS
 CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 314771-31-8 HCAPLUS
 CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 402569-98-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R)-2-(methoxymethyl)-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-52-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2S)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-53-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-58-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyloxy]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-17-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3R]-tetrahydro-3-furanyloxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-18-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3S]-tetrahydro-3-furanyloxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-26-2 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-

quinazolinyl]-4-[(2-methoxyethyl)methylamino]- (9CI) (CA INDEX NAME)



RN 439081-30-8 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(cyclopropylmethylamino)- (9CI) (CA INDEX NAME)



RN 439081-39-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(2R)-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-40-0 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2S)-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 439081-48-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2-methoxyethyl)methylamino]- (9CI) (CA INDEX NAME)



RN 573649-57-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)



IT 402569-87-3 402855-15-6

RL: RCT (Reactant); RACT (Reactant or reagent)


(pharmaceutical compns. for treatment of respiratory tract diseases comprising anticholinergic agents and inhibitors of EGFR-kinase)

RN 402569-87-3 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxy-3-methoxypropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 402855-15-6 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2S)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




IT 314771-48-7 402570-00-7 573649-61-3

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for treatment of respiratory tract diseases
comprising anticholinergic agents and inhibitors of EGFR-kinase)

RN 314771-48-7 HCAPLUS


CN 2-Butenamide, 4- [bis(2-methoxyethyl) amino] -N- [4- [(3-chloro-4-
fluorophenyl) amino] -7- (cyclopropylmethoxy) -6-quinazolinyl] - (9CI) (CA
INDEX NAME)



RN 402570-00-7 HCAPLUS

CN 2-Butenamide, N- [4- [(3-chloro-4-fluorophenyl) amino] -7- (cyclopropylmethoxy) -
6-quinazolinyl] -4- [(2S) -2- (methoxymethyl) -6-oxo-4-morpholinyl] - (9CI) (CA
INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 573649-61-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]methoxy]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:913005 HCAPLUS

DOCUMENT NUMBER: 139:391384

TITLE: Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy

INVENTOR(S): Singer, Thomas; Colbatzky, Florian; Platz, Stefan
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany

SOURCE: PCT Int. Appl., 35 pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003094921	A2	20031120	WO 2003-EP4606	20030502
WO 2003094921	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10221018	A1	20031127	DE 2002-10221018	20020511
CA 2483590	AA	20031120	CA 2003-2483590	20030502
EP 1505981	A2	20050216	EP 2003-727422	20030502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005526123	T2	20050902	JP 2004-503006	20030502
US 2003225079	A1	20031204	US 2003-431699	20030508
PRIORITY APPLN. INFO.:				
			DE 2002-10221018	A 20020511
			US 2002-389815P	P 20020618
			WO 2003-EP4606	W 20030502

OTHER SOURCE(S): MARPAT 139:391384

AB The invention discloses the use of EGF-receptor antagonists for the production of a medicament to prevent and/or treat benign prostatic hyperplasia and/or prostatic hypertrophy, as well as a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy involving the administration of an EGF-receptor antagonist, optionally in combination with known compds. for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, and the corresponding pharmaceutical compns. Compds. of the invention include e.g. quinazoline derivs. and monoclonal antibodies. Preparation of

4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-(N-(2-methoxyethyl)-N-methylamino)-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline is described.


IT 439081-48-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(EGFR-mediated signal transduction inhibitors for treatment of benign prostatic hyperplasia/prostatic hypertrophy)

RN 439081-48-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2-methoxyethyl)methylamino]- (9CI) (CA INDEX NAME)




IT 314771-10-3 314771-31-8 314771-48-7
 439081-10-4 439081-17-1 439081-18-2
 439081-26-2 439081-30-8 439081-39-7
 439081-40-0 573649-57-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (EGFR-mediated signal transduction inhibitors for treatment of benign
 prostatic hyperplasia/prostatic hypertrophy)


RN 314771-10-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-
 6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 314771-31-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-
 6-quinazolinyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 314771-48-7 HCAPLUS

CN 2-Butenamide, 4-[bis(2-methoxyethyl)amino]-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 439081-10-4 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 439081-17-1 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(3R)-tetrahydro-3-furanyloxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 439081-18-2 HCAPLUS
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3-(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 439081-26-2 HCAPLUS
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-[(2-methoxyethyl)methylamino]- (9CI) (CA INDEX NAME)



RN 439081-30-8 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(cyclopropylmethylamino)- (9CI) (CA INDEX NAME)



RN 439081-39-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2R]-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-40-0 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2S]-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 573649-57-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:855936 HCAPLUS

DOCUMENT NUMBER: 139:350749

TITLE: Preparation of 4-aminoquinazolines as inhibitors of epidermal growth factor receptor (EGF-R)

INVENTOR(S): Himmelsbach, Frank; Jung, Birgit; Solca, Flavio

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003089439	A1	20031030	WO 2003-EP3828	20030414
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 DE 10217689 A1 20031113 DE 2002-10217689 20020419
 CA 2484395 AA 20031030 CA 2003-2484395 20030414
 EP 1499619 A1 20050126 EP 2003-746824 20030414
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 US 2004044014 A1 20040304 US 2003-417647 20030417
 US 2005159436 A1 20050721 US 2005-81067 20050315
 PRIORITY APPLN. INFO.: DE 2002-10217689 A 20020419
 US 2002-387021P P 20020607
 WO 2003-EP3828 W 20030414
 US 2003-417647 B1 20030417
 OTHER SOURCE(S): MARPAT 139:350749
 GI



AB Title compds. [I; R1 = H, alkyl; R2 = Ph, benzyl, 1-phenylethyl in which Ph is substituted; R3 = H, F, Cl, Br, OH, alkoxy, fluorinated OMe, OEt, substituted alkoxy; cycloalkyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, etc.; A = imino, alkylimino, B = CO, SO2; C = (substituted) 1,3-allenylene, 1,1-vinylene, 1,2-vinylene, C.tplbond.CH, etc.; D = (branched) alkylene; E = bridged pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, morpholin-4-yl] tautomers, stereoisomers, mixts. and salts thereof, particularly their physiol. compatible salts with inorg. or organic acids, were prepared Thus, a solution of LiCl in H2O was treated with 4-[(3-chloro-4-fluorophenyl)amino]-6-[2-(diethoxyphosphoryl)acetyl amino]-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazoline (preparation given) in THF followed by addition of KOH-pellets and cooling at -3°. Then, the reaction mixture was dropwise treated with (1S,4S)-(2-oxa-5-azabicyclo[2.2.1]hept-5-yl)acetaldehyde hydrochloride (preparation given) for 5 min at 0° followed by stirring for 10 min at 0° and for 20 min at room temperature to give 60% 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]-1-oxo-2-buten-1-yl)amino]-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazoline. The latter inhibited EGF-receptor kinase with IC50 = 0.5 nM. The invention also relates to the use of these compds. for treating diseases, particularly tumor diseases and benign prostatic hyperplasia (BPH), diseases of the lungs and of the respiratory tract.

IT 618061-81-7P 618061-83-9P 618061-84-0P
 618061-85-1P 618061-86-2P 618061-87-3P
 618061-88-4P 618061-89-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of aminoquinazolines as inhibitors of epidermal growth factor
receptor (EGF-R))

RN 618061-81-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-
6-quinazolinyl]-4-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.




RN 618061-83-9 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-
quinazolinyl]-4-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 618061-84-0 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3-(3S)-tetrahydro-3-furanyloxy]-6-quinazolinyl]-4-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]-
(9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry unknown.

RN 618061-85-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3-(3S)-tetrahydro-3-furanyloxy]-6-quinazolinyl]-4-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)]-
(9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry unknown.

RN 618061-86-2 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3-(3S)-tetrahydro-3-furanyloxy]-6-quinazolinyl]-4-(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]-
(9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry unknown.



RN 618061-87-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)]-(9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 618061-88-4 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 618061-89-5 HCAPLUS
 CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:656610 HCAPLUS
 DOCUMENT NUMBER: 139:202486
 TITLE: Inhalants containing anticholinergic agents and EGFR kinase inhibitors
 INVENTOR(S): Jung, Birgit; Pairet, Michel; Pieper, Michael P.
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 14
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068264	A1	20030821	WO 2003-EP1357	20030212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10206505	A1	20030828	DE 2002-10206505	20020216
CA 2476127	AA	20030821	CA 2003-2476127	20030212
EP 1478398	A1	20041124	EP 2003-704593	20030212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

BR 2003007703 A 20050104 BR 2003-7703 20030212
 JP 2005517039 T2 20050609 JP 2003-567444 20030212
 PRIORITY APPLN. INFO.: DE 2002-10206505 A 20020216
 WO 2003-EP1357 W 20030212


AB The invention relates to novel medicinal compns. on the basis of anticholinergic agents and EGFR kinase inhibitors, methods for their production and their use for treating respiratory diseases. Thus a series of quinazoline derivs. were synthesized that were EGFR kinase inhibitors. A typical inhalation powder contained (µg/capsule): tiotropium bromide 10.8; EGFR kinase inhibitor 3500; lactose 3489.2.

IT 290302-19-1P 314771-10-3P 314771-31-8P
 402569-98-6P 402855-52-1P 402855-53-2P
 402855-58-7P 439081-10-4P 439081-17-1P
 439081-18-2P 439081-26-2P 439081-30-8P
 439081-48-8P 573649-57-7P 582311-86-2P
 582311-87-3P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (inhalants containing anticholinergic agents and EGFR kinase inhibitors)


RN 290302-19-1 HCAPLUS

CN β-Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 314771-10-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 314771-31-8 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 402569-98-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R)-2-(methoxymethyl)-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-52-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2S)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-53-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-58-7 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-10-4 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 439081-17-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(3R)-tetrahydro-3-furanyloxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-18-2 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydro-3-furanyloxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 439081-26-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-[(2-methoxyethyl)methylamino]-(9CI) (CA INDEX NAME)




RN 439081-30-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(cyclopropylmethylamino)-(9CI) (CA INDEX NAME)




RN 439081-48-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2-methoxyethyl)methylamino]- (9CI) (CA INDEX NAME)



RN 573649-57-7 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)



RN 582311-86-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3R)-tetrahydro-3-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 582311-87-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3-(3S)-tetrahydro-3-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 402569-87-3 402855-15-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(inhalants containing anticholinergic agents and EGFR kinase inhibitors)

RN 402569-87-3 HCAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxy-3-methoxypropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-15-6 HCAPLUS
 CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2S)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:607455 HCAPLUS
 DOCUMENT NUMBER: 139:159940
 TITLE: Use of tyrosine kinase inhibitors for treatment of pulmonary inflammatory conditions
 INVENTOR(S): Jung, Birgit; Puschner, Hubert
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany

SOURCE: Ger. Offen., 24 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10204462	A1	20030807	DE 2002-10204462	20020205
CA 2472293	AA	20030814	CA 2003-2472293	20030128
WO 2003066060	A2	20030814	WO 2003-EP814	20030128
WO 2003066060	A3	20040115		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1474149	A2	20041110	EP 2003-704477	20030128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005525328	T2	20050825	JP 2003-565484	20030128
US 2003149062	A1	20030807	US 2003-353616	20030129
PRIORITY APPLN. INFO.:			DE 2002-10204462	A 20020205
			WO 2003-EP814	W 20030128

OTHER SOURCE(S): MARPAT 139:159940

AB The invention discloses the use of quinazoline derivs. (Markush included), or the compds. (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-dimethylaminocyclohexyl)amino]pyrimido[5,4-d]pyrimidine; (2) 4-[(R)-(1-phenylethyl)amino]-6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine; (3) 4-[(3-Chloro-4-(3-fluoro-4-benzyloxy)phenyl)amino]-6-[5-((2-methansulfonylethyl)amino)methyl]-furan-2-yl]quinazoline; or the antibody cetuximab C225, trastuzumab, ABX-EGF, Mab ICR-62 and EGFR antisense, their tautomers, their stereoisomers and their salts, in particular their physiol. compatible salts with inorg. or organic acids or bases, for the production of a medication for prevention or treatment of diseases of the respiratory system or the lung. Preparation of quinazoline compds. is included.


IT 314771-48-7P 402855-52-1P 402855-58-7P
 439081-10-4P 439081-17-1P 439081-18-2P
 439081-26-2P 439081-30-8P 439081-39-7P
 439081-40-0P 439081-48-8P 573649-57-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(tyrosine kinase inhibitors for treatment of pulmonary inflammatory conditions)

RN 314771-48-7 HCAPLUS


CN 2-Butenamide, 4-[bis(2-methoxyethyl)amino]-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 402855-52-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2S)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-58-7 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-10-4 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 439081-17-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-18-2 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 439081-26-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-[(2-methoxyethyl)methylamino] - (9CI) (CA INDEX NAME)



RN 439081-30-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(cyclopropylmethylamino) - (9CI) (CA INDEX NAME)




RN 439081-39-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(2R)-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439081-40-0 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(2S)-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 439081-48-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2-methoxyethyl)methylamino]- (9CI) (CA INDEX NAME)



RN 573649-57-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)



IT 290302-19-1 314771-10-3 314771-31-8

402569-98-6 402570-00-7 402855-53-2

573649-60-2 573649-61-3


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(tyrosine kinase inhibitors for treatment of pulmonary inflammatory conditions)


RN 290302-19-1 HCAPLUS

CN β -Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 314771-10-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(dimethylamino)-(9CI) (CA INDEX NAME)



RN 314771-31-8 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-morpholinyl)-(9CI) (CA INDEX NAME)



RN 402569-98-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R)-2-(methoxymethyl)-6-oxo-4-morpholinyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402570-00-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2S)-2-(methoxymethyl)-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.




RN 402855-53-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 573649-60-2 HCAPLUS
 CN 2-Butenamide, 4-[bis(2-methoxyethyl)amino]-N-[4-[(4-chloro-3-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 573649-61-3 HCAPLUS
 CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3S)-tetrahydro-3-furanyl]methoxy]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



IT 402569-87-3 402855-15-6

RL: RCT (Reactant); RACT (Reactant or reagent)


(tyrosine kinase inhibitors for treatment of pulmonary inflammatory conditions)

RN 402569-87-3 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxy-3-methoxypropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 402855-15-6 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2S)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



L4 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:487536 HCAPLUS

DOCUMENT NUMBER: 137:63250

TITLE: Quinazoline derivatives as inhibitors of human EFG tyrosine kinase

INVENTOR(S): Himmelsbach, Frank; Langkopf, Elke; Blech, Stefan; Jung, Birgit; Baum, Elke; Solca, Flavio

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050043	A1	20020627	WO 2001-EP14569	20011212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10063435	A1	20020704	DE 2000-10063435	20001220
CA 2432428	AA	20020627	CA 2001-2432428	20011212
AU 2002019174	A5	20020701	AU 2002-19174	20011212
EP 1345910	A1	20030924	EP 2001-271363	20011212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300300	A	20031015	EE 2003-300	20011212
BR 2001016266	A	20040217	BR 2001-16266	20011212
JP 2004516283	T2	20040603	JP 2002-551540	20011212
US 2002173509	A1	20021121	US 2001-23099	20011217
ZA 2003004141	A	20040415	ZA 2003-4141	20030528

NO 2003002726	A	20030616	NO 2003-2726	20030616
BG 107929	A	20050131	BG 2003-107929	20030619
PRIORITY APPLN. INFO.:			DE 2000-10063435	A 20001220
			US 2000-259201P	P 20001228
			WO 2001-EP14569	W 20011212

OTHER SOURCE(S): MARPAT 137:63250
GI




AB Quinazoline derivs. I [R = PhCH₂, PhCHMe, 3,4-Cl(F)C₆H₃; R₁ = NMeR₂, NEt₂, NEtCH₂CH₂OMe, N(CH₂CH₂OMe)₂, morpholino; R₂ = Me, Et, CHMe₂, cyclopropyl, CH₂CH₂OMe, 3-tetrahydrofuryl, 2-tetrahydrofurylmethyl, 3-tetrahydrofurylmethyl, 4-tetrahydropyranyl, 4-tetrahydropyranylmethyl; R₃ = cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, 3-tetrahydrofuryloxy, 2-tetrahydrofurylmethoxy, 3-tetrahydrofurylmethoxy, 4-tetrahydropyranyloxy, 4-tetrahydropyranylmethoxy] were prepared for use as inhibitors of signal transduction caused by human EFG receptor tyrosine kinase. They are useful in the treatment of tumoral diseases, diseases of the lung and the respiratory tract, the gastrointestinal tract, and the gallbladder and bile ducts. Thus, the quinazoline II was prepared by converting bromocrotonic acid to its chloride, and reaction with 4-[(3-chloro-4-fluorophenyl)amino]-6-amino-7-cyclopropylmethoxyquinazoline, followed by MeNHCH₂CH₂OMe. II had an IC₅₀ against human EFG receptor kinase of 0.7 nM.

IT 439081-10-4P 439081-18-2P 439081-30-8P
439081-40-0P 439081-41-1P 439081-42-2P
439081-48-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as inhibitors of human EFG tyrosine kinase)

RN 439081-10-4 HCAPLUS
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 439081-18-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3-(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.



RN 439081-30-8 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(cyclopropylmethylamino)- (9CI) (CA INDEX NAME)



RN 439081-40-0 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2S]-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-41-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3S]-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(ethylmethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-42-2 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3S]-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-48-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2-methoxyethyl)methylamino]- (9CI) (CA INDEX NAME)




IT 439081-09-1P 439081-16-0P 439081-17-1P
 439081-19-3P 439081-20-6P 439081-21-7P
 439081-22-8P 439081-24-0P 439081-25-1P
 439081-26-2P 439081-27-3P 439081-28-4P
 439081-31-9P 439081-32-0P 439081-34-2P
 439081-35-3P 439081-36-4P 439081-37-5P
 439081-38-6P 439081-39-7P 439081-43-3P
 439081-44-4P 439081-45-5P 439081-46-6P
 439081-47-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazoline derivs. as inhibitors of human EFG tyrosine kinase)


RN 439081-09-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutyloxy)-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 439081-16-0 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutyloxy)-6-quinazolinyl]-4-[methyl[(tetrahydro-3-furanyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 439081-17-1 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3R]-tetrahydro-3-furanyloxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 439081-19-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)oxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 439081-20-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 439081-21-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-3-furanyl)methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 439081-22-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-3-furanyl)methoxy]-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)




RN 439081-24-0 HCAPLUS

CN 2-Butenamide, 4-[bis(2-methoxyethyl)amino]-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 439081-25-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 439081-26-2 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-[(2-methoxyethyl)methylamino]-(9CI) (CA INDEX NAME)



RN 439081-27-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl[(2R)-tetrahydro-2-furanyl]methyl]amino]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-28-4 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl[(2S)-tetrahydro-2-furanyl]methyl]amino]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 439081-31-9 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(cyclopropylmethylanino)- (9CI) (CA INDEX NAME)



RN 439081-32-0 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl[(tetrahydro-2H-pyran-4-yl)methyl]amino]-(9CI)
(CA INDEX NAME)



RN 439081-34-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-[methyl[(2R)-tetrahydro-2-furanyl]methyl]amino]-(9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-35-3 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-[methyl[(2S)-tetrahydro-2-furanyl]methyl]amino]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 439081-36-4 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 439081-37-5 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]-4-(4-morpholinyl)-(9CI) (CA INDEX NAME)



RN 439081-38-6 HCAPLUS


CN 2-Butenamide, 4-[bis(2-methoxyethyl)amino]-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]-(9CI) (CA INDEX NAME)



RN 439081-39-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2R)-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-43-3 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-44-4 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 439081-45-5 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2S]-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(ethylmethlamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-46-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2S]-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-47-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2S)-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-[methyl(1-methylethyl)amino] - (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:171892 HCAPLUS

DOCUMENT NUMBER: 136:216762

TITLE: Preparation of 4-amino-6-heterocyclylcarbonylaminoquinazolines as epidermal growth factor receptor signal transduction inhibitors

INVENTOR(S): Himmelsbach, Frank; Langkopf, Elke; Jung, Birgit; Blech, Stefan; Solca, Flavio

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018376	A1	20020307	WO 2001-EP9536	20010818
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10042062	A1	20020307	DE 2000-10042062	20000826
AU 2001095482	A5	20020313	AU 2001-95482	20010818
CA 2417907	AA	20030130	CA 2001-2417907	20010818
EP 1315720	A1	20030604	EP 2001-976108	20010818
EP 1315720	B1	20050706		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004507538	T2	20040311	JP 2002-523891	20010818
AT 299143	E	20050715	AT 2001-976108	20010818
US 2002115675	A1	20020822	US 2001-934631	20010822
US 6740651	B2	20040525		
PRIORITY APPLN. INFO.:			DE 2000-10042062	A 20000826
			US 2000-230542P	P 20000905
			WO 2001-EP9536	W 20010818

OTHER SOURCE(S): MARPAT 136:216762

GI



AB Title compds. [I; X = N, (substituted) methynyl; R1 = H, Me; R2 = (substituted) Ph, PhCH2, 1-phenylethyl; R3 = H, Me; A = (substituted) vinyl, ethynyl, 1,3-butadien-1,4-yl; B = (substituted) alkenyl, alkenylcarbonyl, etc.; C = (substituted) 2-oxomorpholin-4-yl, etc; D = oxyalkenyl, O; E = (substituted) amino, alkenylimino, imidazolyl, cycloalkyl; or DE = H, (substituted) alkoxy, etc.], were prepared Thus, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-[N-(ethoxycarbonylmethyl)-N-((R)-2-hydroxy-3-methoxypropyl)amino]-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline (preparation given) and MeSO2OH in MeCN were stirred for 4 h under reflux to give 69% 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-[(R)-2-methoxymethyl-6-oxomorpholin-4-yl]-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline. The latter inhibited epidermal growth factor (EGF)-dependent proliferation of F/L-HERc cells with IC50 = 2 nM. The invention relates to the use of the title compds. for treating tumor diseases, and lung and respiratory tract disorders.

IT 402569-98-6P 402569-99-7P 402570-00-7P

402570-01-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (amino)(heterocyclylcarbonylamino)quinazolines as epidermal growth factor receptor signal transduction inhibitors)

RN 402569-98-6 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R)-2-(methoxymethyl)-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 402569-99-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(2-oxo-1,9-dioxaspiro[5.5]undec-4-yl)- (9CI) (CA INDEX NAME)




RN 402570-00-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2S)-2-(methoxymethyl)-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 402570-01-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[2-(2-methoxyethyl)-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)



IT 402569-87-3P 402569-89-5P 402569-90-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (amino)(heterocyclylcarbonylamino)quinazolines as epidermal growth factor receptor signal transduction inhibitors)

RN 402569-87-3 HCAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxy-3-methoxypropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 402569-89-5 HCAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 402569-90-8 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2S)-2-hydroxy-3-methoxypropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:171889 HCAPLUS
 DOCUMENT NUMBER: 136:232315
 TITLE: Preparation of 4-amino-6-vinylcarbonylaminoquinazoline
 s as epidermal growth factor receptor signal
 transduction inhibitors
 INVENTOR(S): Himmelsbach, Frank; Langkopf, Elke; Jung, Birgit;
 Blech, Stefan; Solca, Flavio
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany
 SOURCE: PCT Int. Appl., 78 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018373	A1	20020307	WO 2001-EP9537	20010818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10042060	A1	20020307	DE 2000-10042060	20000826
US 2002077330	A1	20020620	US 2001-929931	20010815
US 6653305	B2	20031125		
CA 2417050	AA	20020307	CA 2001-2417050	20010818
AU 2001084021	A5	20020313	AU 2001-84021	20010818
EP 1315717	A1	20030604	EP 2001-962953	20010818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

JP 2004517048 T2 20040610 JP 2002-523888 20010818
 PRIORITY APPLN. INFO.: DE 2000-10042060 A 20000826
 US 2000-230389P P 20000906
 WO 2001-EP9537 W 20010818

OTHER SOURCE(S): MARPAT 136:232315
 GI



AB Title compds. [I; R1 = PhCH2, 1-phenylethyl, (substituted) Ph; R2 = N-[(1,3-dioxolan-2-yl)methyl]methylamino, (substituted) R4OCOCH2NCH2CH2OH, 2-oxomorpholin-4-yl; R4 = H, alkyl; R3 = H, (alkoxy)alkoxy, cycloalkylalkoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranylmethoxy, tetrahydropyranylmethoxy; n = 1-3], were prepared Thus, a mixture of 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-7-cyclopropylmethoxyquinazoline (preparation given) and diisopropylethylamine in THF was dropwise treated under ice-cooling with BrCH2CH:CHCO2Cl (preparation given) in CH2Cl2 followed by stirring for 1 h under ice-cooling and for 2 h at room temperature and addition of

(S)-(2-hydroxypropylamino)acetic acid tert-Bu ester in CH2Cl2 to give after stirring over night at room temperature and stirring for 5 h at 60° 64% 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-[N-(tert-butyloxycarbonylmethyl)-N-((S)-2-hydroxyprop-1-yl)amino]-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline. Several I inhibited epidermal growth factor (EGF)-dependent proliferation of F/L-HERc cells with IC50 = 0.02-15 nM. The invention relates to the use of the title compds. for treating tumor diseases, and lung and respiratory tract disorders.

IT 402855-15-6P 402855-53-2P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of (amino)(vinylcarbonylamino)quinazolines as epidermal growth factor receptor signal transduction inhibitors)

RN 402855-15-6 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2S)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 402855-53-2 HCAPLUS

CN 2-Butenamide, N- [4- [(3-chloro-4-fluorophenyl)amino] -7- (cyclopropylmethoxy) -6-quinazolinyl] -4- [(2R) -2-methyl-6-oxo-4-morpholinyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 402855-16-7P 402855-17-8P 402855-18-9P
 402855-20-3P 402855-21-4P 402855-22-5P
 402855-23-6P 402855-25-8P 402855-26-9P
 402855-27-0P 402855-28-1P 402855-29-2P
 402855-31-6P 402855-33-8P 402855-34-9P
 402855-35-0P 402855-37-2P 402855-40-7P
 402855-42-9P 402855-46-3P 402855-47-4P
 402855-48-5P 402855-49-6P 402855-50-9P
 402855-51-0P 402855-52-1P 402855-54-3P
 402855-55-4P 402855-56-5P 402855-57-6P
 402855-58-7P 402855-59-8P 402855-60-1P
 402855-62-3P 402855-64-5P 402855-66-7P
 402855-70-3P 402855-71-4P 402855-72-5P

402855-73-6P 402855-74-7P 402855-75-8P

402855-76-9P 402855-77-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (amino)(vinylcarbonylamino)quinazolines as epidermal growth factor receptor signal transduction inhibitors)

RN 402855-16-7 HCAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-17-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(1,3-dioxolan-2-ylmethyl)methylamino]- (9CI) (CA INDEX NAME)




RN 402855-18-9 HCAPLUS

CN L-Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-

hydroxyethyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-20-3 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutyloxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2S)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-21-4 HCAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutyloxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 402855-22-5 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutyloxy)-6-quinazolinyl]-4-(5,5-dimethyl-2-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 402855-23-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(5,5-dimethyl-2-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 402855-25-8 HCAPLUS
 CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(5,5-dimethyl-2-oxo-4-morpholinyl)]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 402855-26-9 HCAPLUS
 CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2S)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 402855-27-0 HCAPLUS
 CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 402855-28-1 HCAPLUS


CN Glycine, N-[4-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 402855-29-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)oxy]-6-quinazolinyl]-4-(5,5-dimethyl-2-oxo-4-morpholinyl)-(9CI) (CA INDEX NAME)




RN 402855-31-6 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)oxy]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-hydroxy-2-methylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 402855-33-8 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]-4-(5,5-dimethyl-2-oxo-4-morpholinyl)-(9CI) (CA INDEX NAME)



RN 402855-34-9 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(5,5-dimethyl-2-oxo-4-morpholinyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 402855-35-0 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(5-ethyl-2-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 402855-37-2 HCAPLUS
 CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-[(3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2S)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 402855-40-7 HCAPLUS
 CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)oxy]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 402855-42-9 HCAPLUS
 CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 402855-46-3 HCAPLUS

CN Glycine, N-[4-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-3-furanyl)methoxy]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 402855-47-4 HCAPLUS

CN 2-Butenamide, N-[4-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-3-furanyl)methoxy]-6-quinazolinyl]-4-(2,2-dimethyl-6-oxo-4-morpholinyl)]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 402855-48-5 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-3-furanyl)methoxy]-6-quinazolinyl]-4-(5,5-dimethyl-2-oxo-4-morpholinyl)-(9CI) (CA INDEX NAME)



RN 402855-49-6 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-50-9 HCAPLUS

CN Glycine, N-[4-[[7-(cyclopropylmethoxy)-4-[(phenylmethyl)amino]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-51-0 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2S)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-52-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazoliny]-4-[(2S)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-54-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazoliny]-4-[(3S)-3-methyl-2-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-55-4 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutyloxy)-6-quinazolinyl]-4-[(2S)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-56-5 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutyloxy)-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-57-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazoliny]-4-[(2S)-2-methyl-6-oxo-4-morpholinyl]]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.




RN 402855-58-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazoliny]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 402855-59-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI)
(CA INDEX NAME)Absolute stereochemistry.
Double bond geometry unknown.


RN 402855-60-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)oxy]-6-quinazolinyl]-4-(2,2-dimethyl-6-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 402855-62-3 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[3R)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-[(2S)-2-methyl-6-oxo-4-morpholinyl]- (9CI)
(CA INDEX NAME)Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-64-5 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)oxy]-6-quinazolinyloxy]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-66-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyloxy]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-70-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-3-furanyl)methoxy]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-71-4 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-72-5 HCAPLUS

CN 2-Butenamide, N-[7-(cyclopropylmethoxy)-4-[(phenylmethyl)amino]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-73-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]-4-[(2S)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-74-7 HCAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 402855-75-8 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-hydroxy-2-methylpropyl)- (9CI)
(CA INDEX NAME)



RN 402855-76-9 HCAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-hydroxy-1,1-dimethylethyl)-(9CI) (CA INDEX NAME)



RN 402855-77-0 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:762992 HCAPLUS

DOCUMENT NUMBER: 135:303907

TITLE: Preparation of quinazolines as inhibitors of epidermal growth factor-mediated signal transduction.

INVENTOR(S): Himmelsbach, Frank; Langkopf, Elke; Jung, Birgit; Blech, Stefan; Solca, Flavio

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077104	A1	20011018	WO 2001-EP3694	20010331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10017539	A1	20011011	DE 2000-10017539	20000408
DE 10040525	A1	20020228	DE 2000-10040525	20000818
CA 2403152	AA	20011018	CA 2001-2403152	20010331
AU 2001063831	A5	20011023	AU 2001-63831	20010331
EP 1280798	A1	20030205	EP 2001-938076	20010331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003530395	T2	20031014	JP 2001-575577	20010331
PRIORITY APPLN. INFO.:			DE 2000-10017539	A 20000408

DE 2000-10040525


A 20000818

WO 2001-EP3694

W 20010331

OTHER SOURCE(S) :
GI

MARPAT 135:303907




AB Title compds. [I; X = NCN, N; R1 = H, alkyl; R2 = (substituted) Ph, PhCH2, PhCH2CH2; R3 = H, alkyl; R4 = H, alkoxy, cycloalkoxy, cycloalkylalkoxy; A = (substituted) vinylene; B = bond, (fluoro)alkylene; D = substituted pyrrolidinyl, piperidinyl, piperazinyl, etc.], were prepared Thus, 4-[(3-chloro-4-fluorophenyl)amino]-6-[[4-(piperazin-1-yl)-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxyquinazoline (preparation given) in THF was treated with Et3N and then with 3-bromodihydrofuran-2-one in THF under ice cooling followed by stirring for 48 h at room temperature to give 56% 4-[(3-chloro-4-fluorophenyl)amino]-6-[[4-[4-(2-oxotetrahydrofuran-3-yl)piperazin-1-yl]-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxyquinazoline. The latter inhibited epidermal growth factor (EGF)-dependent proliferation of F/L-HERc cells with IC50 = 0.05 nM.

IT 365532-35-0P 365532-36-1P 365532-37-2P
365532-39-4P 365532-41-8P 365532-42-9P
365532-44-1P 365532-45-2P 365532-46-3P
365532-47-4P 365532-48-5P 365532-49-6P
367282-07-3P 367282-12-0P 367282-23-3P
367282-25-5P 367282-27-7P 367282-29-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolines as inhibitors of epidermal growth factor-mediated signal transduction)

RN 365532-35-0 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(tetrahydro-2-oxo-3-furanyl)-1-piperazinyl]- (9CI)
(CA INDEX NAME)



RN 365532-36-1 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[(2R)-tetrahydro-5-oxo-2-furanyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 365532-37-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[methyl(tetrahydro-2-oxo-3-furanyl)amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 365532-39-4 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(tetrahydro-5-oxo-3-furanyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 365532-41-8 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[(2S)-tetrahydro-5-oxo-2-furanyl]carbonyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 365532-42-9 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[2-[(tetrahydro-2-oxo-3-furanyl)thio]ethyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 365532-44-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(3-oxo-2-oxa-8-azaspiro[4.5]dec-8-yl)-(9CI) (CA INDEX NAME)



RN 365532-45-2 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(hexahydro-3-oxopyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-(9CI) (CA INDEX NAME)



RN 365532-46-3 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-

6-quinazolinyl]-4-(1-oxo-2-oxa-8-azaspiro[4.5]dec-8-yl)-(9CI) (CA INDEX NAME)




RN 365532-47-4 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(hexahydro-1-oxopyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-(9CI) (CA INDEX NAME)




RN 365532-48-5 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[(tetrahydro-2-oxo-3-furanyl)thio]-1-piperidinyl]-(9CI) (CA INDEX NAME)




RN 365532-49-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[(2,2-dimethyl-6-oxo-4-morpholinyl)methyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 367282-07-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl[1-(tetrahydro-2-oxo-3-furanyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 367282-12-0 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl[1-[(2S)-tetrahydro-5-oxo-2-furanyl]carbonyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


PAGE 1-A



PAGE 1-B

F


RN 367282-23-3 HCAPLUS
 CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-
 6-quinazolinyl]-4-[4-(2-oxo-4-morpholinyl)-1-piperidinyl]- (9CI) (CA
 INDEX NAME)



RN 367282-25-5 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[(2R)-2-methyl-6-oxo-4-morpholinyl]-1-piperidinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 367282-27-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-methyl-2-oxo-1-oxa-4,9-diazaspiro[5.5]undec-9-yl)-(9CI) (CA INDEX NAME)



RN 367282-29-9 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(2-oxo-3-oxa-9-azaspiro[5.5]undec-9-yl)- (9CI) (CA INDEX NAME)




IT 367283-05-4 367283-07-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of quinazolines as inhibitors of epidermal growth factor-mediated signal transduction)

RN 367283-05-4 HCAPLUS


CN Glycine, N-[1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-4-piperidinyl]-N-(2-hydroxyethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 367283-07-6 HCAPLUS

CN Glycine, N-[1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-4-piperidinyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 290303-47-8P 290304-01-7P 365532-06-5P
365532-18-9P 367282-36-8P 367282-44-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolines as inhibitors of epidermal growth factor-mediated signal transduction)


RN 290303-47-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290304-01-7 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 365532-06-5 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(methylamino)-1-piperidyl]- (9CI) (CA INDEX NAME)



RN 365532-18-9 HCAPLUS


CN Carbamic acid, [1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-4-(methylamino)-1-piperidyl]-

piperidinyl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 367282-36-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(methyl-4-piperidinylamino)- (9CI) (CA INDEX NAME)



RN 367282-44-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]methylamino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:747043 HCAPLUS

DOCUMENT NUMBER: 135:303901

TITLE: Bicyclic heterocycles as inhibitors of epidermal growth factor receptor mediated signal transduction

INVENTOR(S): Himmelsbach, Frank; Langkopf, Elke; Jung, Birgit; Blech, Stefan; Solca, Flavio

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma KG, Germany

SOURCE: Ger. Offen., 28 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent



LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10017539	A1	20011011	DE 2000-10017539	20000408
US 2001044435	A1	20011122	US 2001-816003	20010323
US 6627634	B2	20030930		
CA 2403152	AA	20011018	CA 2001-2403152	20010331
WO 2001077104	A1	20011018	WO 2001-EP3694	20010331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001063831	A5	20011023	AU 2001-63831	20010331
EP 1280798	A1	20030205	EP 2001-938076	20010331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003530395	T2	20031014	JP 2001-575577	20010331
PRIORITY APPLN. INFO.:				
			DE 2000-10017539	A 20000408
			DE 2000-10040525	A 20000818
			WO 2001-EP3694	W 20010331

OTHER SOURCE(S) : MARPAT 135:303901
GI



AB Bicyclic heterocycles I [X = N, CCN; R = substituted NH₂; R₁ = H, alkyl; R₂ = acyl; R₃ = H, (un)substituted alkoxy, cycloalkoxy, tetrahydrofuranyloxy, tetrahydropyranyloxy, tetrahydrofuranylmethoxy, tetrahydropyranylmethoxy] were prepared for use as inhibitors of tyrosine kinase-mediated signal transduction for treatment of tumors and diseases of the lung and airway. Thus, 4-[(3-chloro-4-fluorophenyl)amino]-7-fluoro-6-nitroquinazoline was treated with cyclopropylmethanol, followed by reduction to the amine, reaction with 4-bromocrotonic acid and N-tert.-butoxycarbonylpiperazine, and deblocking to give the quinazoline II. II had an IC₅₀ for inhibition of epidermal growth factor dependent proliferation of 0.05 nM.


IT 365532-35-0P 365532-39-4P 365532-42-9P
365532-45-2P 365532-47-4P 365532-48-5P
365532-49-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic heterocycles as inhibitors of epidermal growth factor receptor mediated signal transduction)


RN 365532-35-0 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(tetrahydro-2-oxo-3-furanyl)-1-piperazinyl]- (9CI)
(CA INDEX NAME)




RN 365532-39-4 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(tetrahydro-5-oxo-3-furanyl)-1-piperazinyl]- (9CI)
(CA INDEX NAME)



RN 365532-42-9 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[2-[(tetrahydro-2-oxo-3-furanyl)thio]ethyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 365532-45-2 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[2-[(tetrahydro-5-oxo-3-furanyl)thio]ethyl]-1-piperazinyl]- (9CI)

6-quinazolinyl]-4-(hexahydro-3-oxopyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-
(9CI) (CA INDEX NAME)




RN 365532-47-4 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-
6-quinazolinyl]-4-(hexahydro-1-oxopyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-
(9CI) (CA INDEX NAME)




RN 365532-48-5 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-
6-quinazolinyl]-4-[4-[(tetrahydro-2-oxo-3-furanyl)thio]-1-piperidinyl]-
(9CI) (CA INDEX NAME)



RN 365532-49-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[(2,2-dimethyl-6-oxo-4-morpholinyl)methyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



IT 290303-47-8P 290304-01-7P 365532-06-5P


365532-18-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bicyclic heterocycles as inhibitors of epidermal growth factor receptor mediated signal transduction)


RN 290303-47-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290304-01-7 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 365532-06-5 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(methylamino)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 365532-18-9 HCAPLUS

CN Carbamic acid, [1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 365532-36-1P 365532-37-2P 365532-41-8P


365532-43-0P 365532-44-1P 365532-46-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic heterocycles as inhibitors of epidermal growth factor receptor mediated signal transduction)


RN 365532-36-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[[[(2R)-tetrahydro-5-oxo-2-furanyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 365532-37-2 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[methyl(tetrahydro-2-oxo-3-furanyl)amino]-1-piperidiny]- (9CI) (CA INDEX NAME)



RN 365532-41-8 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[[[(2S)-tetrahydro-5-oxo-2-furanyl]carbonyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 365532-43-0 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(tetrahydro-2-oxo-3-furanyl)-1-piperidinyl]- (9CI)
(CA INDEX NAME)




RN 365532-44-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(3-oxo-2-oxa-8-azaspiro[4.5]dec-8-yl)- (9CI) (CA INDEX NAME)



RN 365532-46-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-oxo-2-oxa-8-azaspiro[4.5]dec-8-yl)-(9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:911231 HCAPLUS

DOCUMENT NUMBER: 134:71599

TITLE: Preparation of aminoquinazolines and aminoquinolines as epidermal growth factor receptor signal transduction inhibitors.

INVENTOR(S): Himmelsbach, Frank; Langkopf, Elke; Metz, Thomas; Solca, Flavio; Jung, Birgit; Baum, Anke

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078735	A1	20001228	WO 2000-EP5547	20000616
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19928281	A1	20001228	DE 1999-19928281	19990621
DE 10023085	A1	20011115	DE 2000-10023085	20000511
CA 2375259	AA	20001228	CA 2000-2375259	20000616
BR 2000011834	A	20020312	BR 2000-11834	20000616
EP 1194418	A1	20020410	EP 2000-936888	20000616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103692	T2	20021021	TR 2001-200103692	20000616
JP 2003502410	T2	20030121	JP 2001-504901	20000616
JP 3686610	B2	20050824		
EE 200100695	A	20030217	EE 2001-695	20000616
AU 775285	B2	20040729	AU 2000-52214	20000616
NZ 516633	A	20040924	NZ 2000-516633	20000616
BG 106189	A	20020830	BG 2001-106189	20011207
US 2002169180	A1	20021114	US 2001-16280	20011210
NO 2001006185	A	20011218	NO 2001-6185	20011218
ZA 2001010351	A	20020618	ZA 2001-10351	20011218
HK 1044769	A1	20050225	HK 2002-106291	20020827
PRIORITY APPLN. INFO.:			DE 1999-19928281	A 19990621
			US 1999-146644P	P 19990730
			DE 2000-10023085	A 20000511
			WO 2000-EP5547	W 20000616

OTHER SOURCE(S): MARPAT 134:71599
 GI



AB Title compds. [I; Ra = H, alkyl; Rb = (substituted) Ph, PhCH₂, PhCH₂CH₂; Rc = (substituted) cycloalkoxy, cycloalkylalkoxy; A = (alkyl-substituted) imino; B = CO, SO₂; C = (substituted) allenylene, vinylene, butadienylene, ethynylene; D = (fluorinated) alkylene, carbonylalkylene, sulfonylalkylene, carbonyloxyalkylene, carbonyliminoalkylene, bond, etc.; E = amino, (substituted) alkylamino, dialkylamino, etc.], were prepared Thus, 6-amino-4-[(3-bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propoxy]quinazoline (preparation given) in CH₂Cl₂ containing Et₃N at -10° was treated with acryloyl chloride in THF to give 35% 4-[(3-bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propoxy]-6-[(vinylcarbonyl)amino]quinazoline. The latter inhibited EGF-dependent proliferation of F/L HERC cells with IC₅₀ = <0.35 nM.


IT 314771-10-3P 314771-31-8P 314771-32-9P
 314771-33-0P 314771-34-1P 314771-35-2P
 314771-36-3P 314771-37-4P 314771-38-5P
 314771-45-4P 314771-46-5P 314771-47-6P
 314771-48-7P 314771-49-8P 314771-50-1P
 314771-51-2P 314771-52-3P 314771-53-4P

314771-54-5P 314771-55-6P 314771-56-7P
 314771-57-8P 314771-58-9P 314771-59-0P
 314771-60-3P 314771-61-4P 314771-62-5P
 314771-63-6P 314771-64-7P 314771-65-8P
 314771-66-9P 314771-67-0P 314771-68-1P
 314771-69-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminoquinazolines and aminoquinolines as epidermal growth factor receptor signal transduction inhibitors)


RN 314771-10-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 314771-31-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 314771-32-9 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-ethyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 314771-33-0 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(2,6-dimethyl-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 314771-34-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-oxido-4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




RN 314771-35-2 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutyloxy)-6-quinazolinyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 314771-36-3 HCAPLUS
 CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 314771-37-4 HCAPLUS
 CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutyloxy)-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)




RN 314771-38-5 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)



RN 314771-45-4 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl(1-methyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RN 314771-46-5 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI) (CA

INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 314771-47-6 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 314771-48-7 HCAPLUS

CN 2-Butenamide, 4-[bis(2-methoxyethyl)amino]-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]- (9CI) (CA
INDEX NAME)




RN 314771-49-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[ethyl(2-methoxyethyl)amino]-(9CI) (CA INDEX NAME)




RN 314771-50-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-piperidinyl)-(9CI) (CA INDEX NAME)




RN 314771-51-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(2-methyl-1-piperidinyl)-(9CI) (CA INDEX NAME)




RN 314771-52-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 314771-53-4 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(cyclopropylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 314771-54-5 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-

6-quinazolinyl]-4-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 314771-55-6 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)



RN 314771-56-7 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R,6S)-2,6-dimethyl-1-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 314771-57-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(2,5-dimethyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 314771-58-9 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)




RN 314771-59-0 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 314771-60-3 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[(diethylamino)methyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 314771-61-4 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(cyclopropylmethyl)methylamino]- (9CI) (CA INDEX NAME)




RN 314771-62-5 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2-methoxycyclopropyl)methylamino]-(9CI) (CA INDEX NAME)




RN 314771-63-6 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(3-methoxypropyl)methylamino]-(9CI) (CA INDEX NAME)




RN 314771-64-7 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-methoxy-1-piperidinyl) (9CI) (CA INDEX NAME)




RN 314771-65-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-hydroxy-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 314771-66-9 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)oxy]-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)



RN 314771-67-0 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)

6-quinazolinyll]-4-[methyl[(tetrahydro-2-furanyl)methyl]amino]-(9CI) (CA INDEX NAME)




RN 314771-68-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyll]-4-[methyl(tetrahydro-3-furanyl)amino]-(9CI) (CA INDEX NAME)



RN 314771-69-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyll]-4-[(2-methoxy-1-methylethyl)methylamino]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 18 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:628125 HCAPLUS

DOCUMENT NUMBER: 133:207919

TITLE: Preparation of 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases useful for treating tumoral diseases, lung and respiratory tract diseases

INVENTOR(S): Himmelsbach, Frank; Langkopf, Elke; Jung, Birgit; Metz, Thomas; Solca, Flavio; Blech, Stefan

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 232 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051991	A1	20000908	WO 2000-EP1496	20000224
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19908567	A1	20000831	DE 1999-19908567	19990227
DE 19911366	A1	20000921	DE 1999-19911366	19990315
DE 19928306	A1	20001228	DE 1999-19928306	19990621
DE 19954816	A1	20010517	DE 1999-19954816	19991113
CA 2361174	AA	20000908	CA 2000-2361174	20000224
EP 1157011	A1	20011128	EP 2000-910695	20000224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008524	A	20011218	BR 2000-8524	20000224
JP 2002538145	T2	20021112	JP 2000-602218	20000224
EE 200100449	A	20021216	EE 2001-449	20000224
BG 105765	A	20020329	BG 2001-105765	20010801
HR 2001000617	A1	20021031	HR 2001-617	20010823
NO 2001004114	A	20011015	NO 2001-4114	20010824
PRIORITY APPLN. INFO.:			DE 1999-19908567	A 19990227
			DE 1999-19911366	A 19990315
			DE 1999-19928306	A 19990621
			US 1999-149329P	P 19990817
			DE 1999-19954816	A 19991113
			WO 2000-EP1496	W 20000224
OTHER SOURCE(S):	MARPAT 133:207919			
GI				



I



II

AB Title compds. [I; R1 = H, C1-C4-alkyl; R2 = (un)substituted Ph, benzyl, 1-phenylethyl; R3, R4 independently = H, F, Cl, CH3O, CH3OCH2, (CH3)2NCH2, (CH3CH2)2NCH2, pyrrolidino, piperidino, morpholino; X = C(CN), N; A = O, NH, (C1-C4)-alkylN; B = CO, SO2; C = 1,3-allenylene, 1,1-vinylene, 1,2-vinylene, 1,3-butadien-1,4-ylene, with CH3, CF3 substitution; D = alkylene, CO-alkylene, SO2-alkylene; CO, SO2; E = HOCO(CH2)nNR5, (HO)2P(:O)(CH2)nNR5; n = 1-6; R5 = H, alkyl], tautomers, stereoisomers, and physiol. acceptable salts are prepared and having valuable pharmacol. properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases. Title compds. are useful for treating tumoral diseases, diseases of the lungs and respiratory tract. Thus, the title compound II was prepared and tested by Cell Titer 96TM Aqueous Nonradioactive Cell Proliferation Assay.


IT 290302-11-3P 290302-19-1P 290302-25-9P
290302-33-9P 290302-47-5P 290302-98-6P
290303-04-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoquinazoline and aminoquinoline derivs. having an inhibitory effect on signal transduction mediated by tyrosine kinases useful for treating tumoral diseases, lung and respiratory tract diseases)


RN 290302-11-3 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-19-1 HCAPLUS

CN β -Alanine, N-[4-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 290302-25-9 HCAPLUS


CN 2-Butenamide, N-[4-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(2-oxo-4-morpholinyl)]- (9CI) (CA INDEX NAME)



RN 290302-33-9 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutyloxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI)


(CA INDEX NAME)



RN 290302-47-5 HCAPLUS


CN L-Proline, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 290302-98-6 HCAPLUS

CN Glycine, N-[2-(acetylthio)ethyl]-N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 290303-04-7 HCAPLUS

CN Glycine, N-[2-(acetyloxy)ethyl]-N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 290303-47-8P 290303-84-3P 290304-01-7P


290304-02-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoquinazoline and aminoquinoline derivs. having an inhibitory effect on signal transduction mediated by tyrosine kinases useful for treating tumoral diseases, lung and respiratory tract diseases)


RN 290303-47-8 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290303-84-3 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[2-[(methylsulfonyl)oxy]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 290304-01-7 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 290304-02-8 HCAPLUS

CN 1,3-Piperazinedicarboxylic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-,
1-(1,1-dimethylethyl) 3-ethyl ester (9CI) (CA INDEX NAME)




IT 290303-13-8P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)

(preparation of aminoquinazoline and aminoquinoline derivs. having an
inhibitory effect on signal transduction mediated by tyrosine kinases
useful for treating tumoral diseases, lung and respiratory tract
diseases)

RN 290303-13-8 HCAPLUS

CN 2-Piperazinecarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(
(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester
(9CI) (CA INDEX NAME)



IT 290301-81-4P 290301-82-5P 290302-09-9P
290302-15-7P 290302-21-5P 290302-23-7P
290302-27-1P 290302-29-3P 290302-31-7P
290302-35-1P 290302-37-3P 290302-41-9P
290302-43-1P 290302-45-3P 290302-49-7P
290302-51-1P 290302-53-3P 290302-55-5P
290302-57-7P 290302-59-9P 290302-61-3P
290302-63-5P 290302-65-7P 290302-67-9P
290302-69-1P 290302-71-5P 290302-73-7P


290302-81-7P 290302-83-9P 290302-85-1P
 290302-87-3P 290302-89-5P 290302-91-9P
 290302-93-1P 290302-94-2P 290303-00-3P
 290303-02-5P 290303-03-6P 290303-05-8P
 290303-06-9P 290303-07-0P 290303-08-1P
 290303-09-2P 290303-10-5P 290303-11-6P
 290303-12-7P 290303-14-9P 290303-15-0P
 290303-16-1P 290303-17-2P 290303-18-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoquinazoline and aminoquinoline derivs. having an inhibitory effect on signal transduction mediated by tyrosine kinases useful for treating tumoral diseases, lung and respiratory tract diseases)

RN 290301-81-4 HCAPLUS


CN 1-Piperazineacetic acid, 4-[4-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-1,4-dioxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 290301-82-5 HCAPLUS


CN L-Proline, 1-[4-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-1,4-dioxo-2-butenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 290302-09-9 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-15-7 HCAPLUS

CN Propanedioic acid, [[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]methylamino]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 290302-21-5 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 290302-23-7 HCAPLUS


CN β -Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(3-ethoxy-3-oxopropyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 290302-27-1 HCAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)

6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-hydroxyethyl)-, ethyl ester
(9CI) (CA INDEX NAME)




RN 290302-29-3 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclohexylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester
(9CI) (CA INDEX NAME)




RN 290302-31-7 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclohexyloxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 290302-35-1 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester
(9CI) (CA INDEX NAME)




RN 290302-37-3 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester
(9CI) (CA INDEX NAME)




RN 290302-41-9 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester
(9CI) (CA INDEX NAME)




RN 290302-43-1 HCAPLUS

CN Glycine, N-[4-[4-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-hydroxy-2-methylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-45-3 HCAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-[4-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, methyl ester
(9CI) (CA INDEX NAME)




RN 290302-49-7 HCAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-methoxy-2-oxoethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 290302-51-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(5,5-dimethyl-2-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 290302-53-3 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(5-methyl-2-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 290302-55-5 HCAPLUS

CN D-Proline, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 290302-57-7 HCAPLUS

CN 2,5-Pyrrolidinedicarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, diethyl ester, (2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 290302-59-9 HCAPLUS

CN 2,6-Piperidinedicarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, dimethyl ester, (2R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 290302-61-3 HCAPLUS

CN 2,6-Piperidinedicarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, dimethyl ester, (2R,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 290302-63-5 HCAPLUS

CN 2,5-Pyrrolidinedicarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, dimethyl ester, (2R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 290302-65-7 HCAPLUS


CN 2,5-Pyrrolidinedicarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, dimethyl ester, (2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 290302-67-9 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-1-methyl-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-69-1 HCAPLUS

CN Butanedioic acid, [4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutyloxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-1-piperazinyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 290302-71-5 HCAPLUS


CN Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 290302-73-7 HCAPLUS


CN L-Proline, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 290302-81-7 HCAPLUS

CN 2-Piperidineacetic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 290302-83-9 HCAPLUS

CN Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-85-1 HCAPLUS

CN L-Proline, 1-[4-[[7-(cyclopropylmethoxy)-4-[(phenylmethyl)amino]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.



RN 290302-87-3 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[7-(cyclopropylmethoxy)-4-[(phenylmethyl)amino]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-89-5 HCAPLUS

CN D-Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-hydroxyethyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 290302-91-9 HCAPLUS

CN 1H-1,4-Diazepine-1-acetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]hexahydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-93-1 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl(tetrahydro-2-oxo-3-furanyl)amino]- (9CI) (CA INDEX NAME)




RN 290302-94-2 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl (tetrahydro-5-oxo-3-furanyl)amino]- (9CI) (CA INDEX NAME)



RN 290303-00-3 HCAPLUS


CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]- (9CI) (CA INDEX NAME)



RN 290303-02-5 HCAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]- (9CI) (CA INDEX NAME)


6-quinazolinyll]-4-(2,2-dimethyl-6-oxo-4-morpholinyl)-(9CI) (CA INDEX NAME)



RN 290303-03-6 HCAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyll]-4-[(3R)-3-methyl-2-oxo-4-morpholinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 290303-05-8 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyll]amino]-4-oxo-2-butenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 290303-06-9 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 290303-07-0 HCAPLUS


CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, 2,3-dihydro-1H-inden-5-yl ester (9CI) (CA INDEX NAME)



RN 290303-08-1 HCAPLUS


CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-

(cyclopropylmethoxy)-6-quinazolinyl] amino]-4-oxo-2-butenyl]-, cyclohexylmethyl ester (9CI) (CA INDEX NAME)




RN 290303-09-2 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl) amino]-7-(cyclopropylmethoxy)-6-quinazolinyl] amino]-4-oxo-2-butenyl]-, octyl ester (9CI) (CA INDEX NAME)




RN 290303-10-5 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl) amino]-7-(cyclopropylmethoxy)-6-quinazolinyl] amino]-4-oxo-2-butenyl]-, hexyl ester (9CI) (CA INDEX NAME)




RN 290303-11-6 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-3-(ethoxycarbonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 290303-12-7 HCAPLUS

CN 1-Piperazinebutanoic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290303-14-9 HCAPLUS

CN 2-Piperazinecarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 290303-15-0 HCAPLUS

CN 2-Piperazinecarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-4-(methylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 290303-16-1 HCAPLUS

CN 1-Piperazinepropanoic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290303-17-2 HCAPLUS

CN 1-Piperazineacetic acid, 4-[4-[4-[4-(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-1,1-dimethyl-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 290303-18-3 HCAPLUS

CN 2-Piperazinecarboxylic acid, 4-acetyl-1-[4-[4-[4-(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT